Provided by Tiger Trade Technology Pte. Ltd.

CARSGEN-B

13.360
+0.1501.14%
Volume:1.90M
Turnover:25.06M
Market Cap:7.94B
PE:-75.37
High:13.410
Open:13.330
Low:12.950
Close:13.210
52wk High:28.600
52wk Low:10.870
Shares:594.00M
HK Float Shares:594.00M
Volume Ratio:0.48
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.177
ROE:-9.57%
ROA:-8.91%
PB:6.18
PE(LYR):-75.37
PS:49.76

Loading ...

CARsgen Therapeutics Holdings (SEHK:2171) Gains Clinical Momentum Following Satri Cel Trial Update But Looks Pricey

Simply Wall St.
·
Jul 27

CARSGEN-B Allocates HK$4.98 Million for Share Buyback on July 17

Stock News
·
Jul 17

Carsgen Files HKEX Next-day Disclosure Return, Issues 2,000 New Shares Via Option Exercise

Reuters
·
Jul 17

Movement Alert|CARsgen Therapeutics-B Falls 6.03% in Regular Trading, Biotech Sector Under Broad Selling Pressure

Market Focus
·
Jul 17

CARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog

Deep News
·
Jul 16

Movement Alert|CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation

Market Focus
·
Jul 16

Hong Kong Stocks Midday Update: Hang Seng Index Rises 1.46%, Innovation Pharma Soars

Stock News
·
Jul 15

Shares of CARSGEN-B Surge Over 6% Ahead of Key Study Presentation at 2026 ESMO Congress

Stock News
·
Jul 15

Movement Alert|CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation

Market Focus
·
Jul 15

CARsgen’s Satri-cel Shows No Post-operative Recurrence in IIT; Data Accepted for Presentation at ESMO 2026

Bulletin Express
·
Jul 15

Carsgen Says Satri-cel Gastric Cancer Consolidation Trial Shows no Recurrences to Date

Reuters
·
Jul 15

Carsgen Files HKEX Next-day Disclosure Return Reporting Share Repurchase and Cancellation

Reuters
·
Jul 07

CARsgen Keeps Share Structure Steady in June 2026; 17.68 Million Options Remain Outstanding

Bulletin Express
·
Jul 07

Movement Alert|CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns

Market Focus
·
Jul 07

CARsgen Therapeutics (SEHK:2171) Is Up 20.8% After First Solid Tumor CAR T Approval - What's Changed

Simply Wall St.
·
Jul 04

Movement Alert|CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound

Market Focus
·
Jul 03

Movement Alert|CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound

Market Focus
·
Jul 02

Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced?

Simply Wall St.
·
Jun 30

Movement Alert|CARsgen Therapeutics-B Rises 6.31% in Regular Trading, Buyback Plan and Sector Recovery Fuel Rebound

Market Focus
·
Jun 29

CARSGEN-B Shares Surge in Afternoon Trading Following Share Buyback Plan Announcement

Stock News
·
Jun 26